We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Treatment Speeds Recovery of Heart Muscle

By Biotechdaily staff writers
Posted on 14 Dec 2004
Researchers have found that damage to heart tissue caused by oxygen deprivation during a heart attack may be reduced and repaired more quickly by treatment with the embryonic cardiac protein thymosin beta-4.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) created a mouse model for heart attack by tying off the coronary arteries in a group of 58 experimental animals. More...
Half of the group was then treated with injections of thymosin beta-4 while the rest of the mice received injections of saline solution.

Results published in the November 25, 2004, edition of Nature revealed that treatment with thymosin beta-4 reduced the number of muscle cells that died as a result of the "heart attack” and stimulated the recovery of muscle mass. The mode of action of thymosin beta-4 was shown to be through the formation of a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt (also known as protein kinase B). This activity at the molecular level resulted in increased rates of cardiomyocyte migration, survival, and repair.

"If the protein has a similar effect in humans as it does in mice, the impact by sheer volume is great--nearly 1 million people have heart attacks every year just in the United States,” said senior author Dr. Deepak Srivastava, professor of molecular biology and pediatrics at the University of Texas Southwestern Medical Center. "The delivery is very simple and avoids many of the problems of using stem cells.”



Related Links:
University of Texas Southwestern Medical Center

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.